Using wearable devices to monitor heart attack patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study explores the use of wearable technology to monitor patients with acute myocardial infarction (AMI) who are receiving primary percutaneous coronary intervention (PCI). Patients will wear devices that track vital signs such as heart rate, blood pressure, and sleep patterns during their stay in the Cardiac Intensive Care Unit. The collected data will be analyzed using AI and machine learning to predict clinical outcomes and improve patient management. Follow-ups will assess cardiac function and quality of life over time.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18-75 years old
* Diagnosed with STEMI or NSTEMI (ACC/AHA guidelines)
* Half male and half female
* Undergo CAG and PCI treatment;
* Written informed consent.

Exclusion Criteria:

* People under the age of 18 years old;
* Patients who are pregnant/breastfeeding;
* Patients who are allergic to the metallic or plastic components of the wearable devices

Where it's running

• Renji Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Zhiguo Zou, MD, PhD
• Email: zouzhiguo@renji.com
• Phone: +86 13524596108

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Adenosine given before primary PCI to reduce no-reflow in STEMI patients.

  See if giving intracoronary adenosine before primary PCI lowers the chance of slow flow/no-reflow in adults with STEMI.

  Recruiting at 2 sites Phase 4 National Institute of Cardiovascular Diseases, Pakistan · Karachi, Sindh and 1 other locations · NCT07536802

• Subclinical depression in people after a first heart attack (SUBDIMA25)

  This project will test how common mild depressive symptoms are in adults hospitalized for a first heart attack and whether those symptoms relate to biomarkers, heart function, and recovery over the next year.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, Italia · NCT07492537

• Long-term follow-up after Hearticellgram-AMI treatment

  We will follow people who got one dose of Hearticellgram-AMI after a heart attack for up to 60 months to see if the treatment stays safe.

  Recruiting Pharmicell Co., Ltd. · Seoul, Gangnam · NCT07400458

• Long-term remote ischemic preconditioning after a heart attack

  This trial will test whether daily brief arm blood‑flow restriction after a recent heart attack can lower the chance of major heart and brain events over the following year for people treated for acute myocardial infarction.

  Recruiting Henan Institute of Cardiovascular Epidemiology · Zhengzhou, Henan · NCT07181356

• Assessing heart tissue damage in patients with heart aneurysms after a heart attack

  This study is testing how heart tissue damage looks in patients with heart aneurysms after a heart attack using special imaging to see if it helps understand their condition better.

  Recruiting RenJi Hospital · Shanghai · NCT06994221

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.